Metabolic dysfunction-associated steatotic liver disease (MASLD) currently represents a significant global health challenge. Traditionally, clinicians have relied on invasive liver biopsies to stage this condition. However, recent advancements in liquid biopsy techniques highlight the potential of cfDNA in MASLD diagnosis. This approach utilizes circulating cell-free DNA to assess hepatic health without the risks associated with tissue sampling. Specifically, researchers look for signs of genomic instability within the bloodstream.

One of the most dynamic markers in this field is mitochondrial DNA copy number (mtDNAcn). Notably, researchers have identified a biphasic response in mtDNAcn that reflects oxidative stress levels. Specifically, early stages of the disease often show a compensatory upregulation. Conversely, advanced fibrosis typically leads to mtDNA depletion. Consequently, this transition makes it a valuable metric for tracking disease progression over time.

Improving Specificity with cfDNA in MASLD Diagnosis

The evolving landscape also includes specific nuclear copy number variations (CNVs) that drive fibrogenesis. For example, the XPO4 duplication at 13q12.11 and deletions in CES1 and ACOT1 play crucial roles in lipid metabolism dysregulation. Therefore, identifying these genomic signatures helps doctors understand the underlying mechanistic drivers of a patient\'s condition. In addition, these variations serve as markers for severe fibrosis.

Beyond simple quantification, emerging multi-modal metrics like DNA methylation and fragmentomics offer superior specificity. These technologies allow scientists to trace the exact tissue of origin. Furthermore, fragmentomics can distinguish between apoptotic and necrotic cell death patterns. This capability effectively addresses the diagnostic challenges of the \"burnout\" phenomenon often seen in advanced cirrhosis. Essentially, these tools provide a clearer picture of the liver\'s state than traditional blood tests. Moreover, they enhance the accuracy of staging.

Integrating these biomarkers with machine learning and multi-omics data remains a priority for future research. Standardized pre-analytical protocols will eventually transition cfDNA from a research tool into a precise clinical instrument. Consequently, this technology will likely become standard for early risk stratification and therapeutic monitoring in the near future.

Frequently Asked Questions

What are the benefits of using cfDNA over traditional liver biopsies?

Using cfDNA offers a non-invasive alternative that reduces patient risk and discomfort. It allows for repeated monitoring and provides a more comprehensive view of hepatic genomic instability compared to a localized tissue sample.

How does mtDNA copy number help in staging MASLD?

Mitochondrial DNA copy number acts as a dynamic marker of oxidative stress. It increases during early compensatory phases but decreases significantly as fibrosis becomes advanced, helping clinicians distinguish between disease stages.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Lim WY et al. From Genomic Instability to Epigenetic Signatures: The Evolving Landscape of Circulating Cell-free DNA in Metabolic Dysfunction-Associated Steatotic Liver Disease. Hepatol Res. 2026 May 02. doi: 10.1111/hepr.70198. PMID: 42068200.

Eslam M et al. Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. EBioMedicine. 2021;70:103521.

Loomba R et al. Mechanisms and future directions of non-invasive tests in MASLD. Nature Reviews Gastroenterology & Hepatology. 2024;21:1-15.